OLAPARIB + PLACEBO
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum Sensitive Relapsed Ovarian Cancer
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Trial Timeline
Jul 1, 2016 → Jun 1, 2019
NCT ID
NCT02392676About OLAPARIB + PLACEBO
OLAPARIB + PLACEBO is a phase 3 stage product being developed by AstraZeneca for Platinum Sensitive Relapsed Ovarian Cancer. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02392676. Target conditions include Platinum Sensitive Relapsed Ovarian Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02392676 | Phase 3 | Withdrawn |
| NCT02032823 | Phase 3 | Active |
Competing Products
20 competing products in Platinum Sensitive Relapsed Ovarian Cancer